Improvement of psychiatric symptoms and social function of aripiprazole long acting injection for outpatient schizophrenia
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000041120
- Lead Sponsor
- Sanzyukai Medical Corporation Naomasa Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who do not meet the above selection criteria.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method For patients who have been treated with aripiprazole LAI for more than 1 year from May 2015 to July 2020, the social function before and after switching from the previous drug will be evaluated by SOFAS according to the patient background.
- Secondary Outcome Measures
Name Time Method The improvement of psychotic symptoms is also evaluated by CGI-I. Treatment continuation rate. Timing of improvement depending on the number of doses